lung cancer

News

BMS pulls Opdivo/Yervoy in first-line lung cancer

Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.

News

FDA extends review of Merck & Co's Keytruda in lung cancer u...

US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company subm

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

News

AbbVie suffers fresh setback with lung cancer drug Rova-T

AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.

News

KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Thousands to benefit as NHS funds Keytruda lung cancer combo

NICE has said MSD’s cancer immunotherapy, Keytruda, should receive interim funding on the NHS in certain patients with untreated lung cancer, in combination with chemotherapy.

News

AstraZeneca's immunotherapy fails in key lung cancer trial

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck

BMS pulls Opdivo/Yervoy in first-line lung cancer

FDA extends review of Merck & Co's Keytruda in lung cancer u...

AZ's cancer drug fails again, Roche's rival gets new use

AbbVie suffers fresh setback with lung cancer drug Rova-T

Thousands to benefit as NHS funds Keytruda lung cancer combo

AstraZeneca's immunotherapy fails in key lung cancer trial

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks